Growth and late-stage private equity fund research profile
Kotak Pre-IPO Opportunities Fund is a 2021 growth and late-stage private-equity vehicle investing in businesses approaching public-market scale. Kotak’s official portfolio page provides a named portfolio list, while 2025 IPO and regulatory records show the fund remained an attributable shareholder in Sahajanand Medical Technologies.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Kotak Pre-IPO Opportunities Fund uses a growth and late-stage private equity; pre-ipo approach across Consumer, technology, financial services, healthcare.
Current evidence
Sahajanand Medical Technologies’ 2025 DRHP and subsequent IPO coverage identify Kotak Pre-IPO Opportunities Fund as a selling shareholder; Kotak’s current private-equity page continues to identify the fund’s portfolio and exited holdings.
Strategy
Growth and late-stage private equity; pre-IPO
Sector focus
Consumer, technology, financial services, healthcare
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Sahajanand Medical Technologies’ 2025 DRHP and subsequent IPO coverage identify Kotak Pre-IPO Opportunities Fund as a selling shareholder; Kotak’s current private-equity page continues to identify the fund’s portfolio and exited holdings.
Investor questions
Kotak Pre-IPO Opportunities Fund is covered in Rupeia's private equity research universe. The current public record describes the strategy as Growth and late-stage private equity; pre-IPO, with a sector focus of Consumer, technology, financial services, healthcare. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Kotak Pre-IPO Opportunities Fund in the reviewed public sources: PharmEasy; Pine Labs; MPL; Policybazaar; Dailyhunt/Josh; Swiggy; Licious; NSE; Nykaa; Cyient DLM; SBFC; Tata Technologies; Sahajanand Medical Technologies. It does not represent a complete current portfolio unless the manager has published one.
Kotak’s official portfolio page marks Policybazaar, Nykaa, Cyient DLM, SBFC and Tata Technologies as exited; Sahajanand Medical Technologies’ 2025 IPO filings and coverage identify Kotak Pre-IPO Opportunities Fund as a selling shareholder. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: $250 million, as reported on Kotak’s official private-equity page; fund-level NAV and return metrics are not publicly disclosed.. Public terms or access information: Growth/late-stage and pre-IPO investments in Indian companies; ticket sizes, fees, carry, reserves and holding period are not publicly disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Rahul Shah (Managing Partner, Kotak Alternate Asset Managers); Dhiraj Rajendran (Partner, Private Equity); Srini Sriniwasan (Managing Director). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Fund-level net returns, fees, carry, reserve policy and complete current holdings are not publicly disclosed. Kotak’s official page identifies 13 investments and marks several exits; the record does not infer ownership percentages or current status beyond those public disclosures..
2025-11-25: Sahajanand Medical Technologies’ 2025 DRHP and subsequent IPO coverage identify Kotak Pre-IPO Opportunities Fund as a selling shareholder; Kotak’s current private-equity page continues to identify the fund’s portfolio and exited holdings.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.